Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT06293651RecruitingPhase 1/Phase 2
Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
SeoulAges 18 years+ - NCT06085222Recruiting
App and computer study for stress in daily cannabis users
This study tests if a smartphone app and computer program can help regular cannabis users manage stress. It is for people who use cannabis daily or nearly daily and feel stressed.
Tallahassee, FloridaAges 18–30 - NCT05951595RecruitingPhase 3
Testing three malaria medicines together versus two
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
Ruhuha, Eastern ProvinceAges 6 months+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Los Angeles, CaliforniaAges 18 years+ - NCT05683717RecruitingPhase 1
First-dose test of TT-01488 for B-cell cancers
This Phase 1 study tests whether TT-01488 is safe and tolerable in people with B-cell malignancies (blood cancers). It’s meant for patients whose disease has come back or did not respond after standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT05756322RecruitingPhase 1/Phase 2
Study medicine LBS-007 for relapsed leukemia patients
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Tampa, FloridaAges 18–120 - NCT05777330Recruiting
Monitoring blood sugar swings to predict type 1 diabetes
This study watches blood sugar changes over time in people who do not yet have diabetes but have test results that suggest risk for type 1 diabetes. The goal is to see whether “blood sugar variability” can predict when high or low blood sugar may happen, even before symptoms.
Liège, LiègeAges 5–39 - NCT05620017RecruitingPhase 1
Early test of an injection for advanced solid tumors
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05244551RecruitingPhase 1
First study drug for advanced cancers with FGFR changes
This early-phase study tests the safety and best dose of ABSK061 in people with advanced solid tumors. It may help people whose cancers have specific FGFR2/3 gene changes, especially urothelial cancer or cholangiocarcinoma.
Dallas, TexasAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT05319353RecruitingPhase 3
Maribavir for kids with CMV after transplant
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Wilmington, DelawareAges Up to 17 years - NCT05086003RecruitingPhase 2
Kidney transplant with stem cell treatment to build immune tolerance
This Phase 2 study tests a combined treatment—kidney transplant plus stem cell–based immune therapy—to help the body accept the new kidney with less immune attack. You may be able to take part if you have a matching sibling donor and meet key safety and health requirements.
Petah TikvaAges 18–65 - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT04495296RecruitingPhase 1/Phase 2
TST001 for advanced or metastatic solid tumors
This Phase 1/2 study tests TST001, and sometimes a combination with other cancer medicines, to see how safe it is and how well it may work in advanced or metastatic solid tumors. You might be eligible if you have certain tumor types and lab/health requirements, and if your tumor tissue shows specific marker results (depending on the study part).
Bengbu, AnhuiAges 18 years+ - NCT04627428RecruitingPhase 1/Phase 2
Stem-cell–made eye tissue transplant for dry macular degeneration
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
Beverly Hills, CaliforniaAges 55 years+ - NCT06217861RecruitingPhase 1
Gene therapy for children with GA-1 not helped by standard care
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
Hangzhou, ZhejiangAges Up to 6 years - NCT06824987RecruitingPhase 2
Study of AZD2373 for APOL1-related kidney disease
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
Alabaster, AlabamaAges 18–65 - NCT07117474RecruitingPhase 1
Testing a single injection for mild high blood pressure
This trial tests a single injection of HRS-9563 in people with mild hypertension (blood pressure 130-159 mmHg) to see if it is safe and how the body processes it. You must not be taking any blood pressure medicines now.
Hangzhou, ZhejiangAges 18–65
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 952 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.